ADVERTORIAL FEATURE
learning ’ techniques that involve learning the skill from corrected mistakes and imitation . “ Unlike rivals in the autonomous vehicles field , it doesn ’ t use highdefinition maps and expensive sensors ,” adds Mileva . “ So the learning isn ’ t limited to the geographical areas they ’ ve already been ‘ taught ’. The aim is to teach the car to drive anywhere .” The company is still privately owned . The Trust took a stake under new rules that let it invest up to 10 per cent of its holdings in unlisted firms . Mileva lists the potential benefits of self-driving vehicles as improved road safety , fewer emissions , more efficient delivery of goods and greater access to transport for millions of people .
This pharma tech company “ precision engineers ” drugs tailored to individual cancer patients and those with other diseases . This involves using artificial intelligence at each stage of the drug discovery and development process . “ The company is made up of a 50-50 split between biologists and technologists ,” Mileva says . “ From the AI generation of the first novel molecules to the design of a potential therapy typically takes Exscientia around 12 months . The industry average is four and a half years .” The firm has 25 new therapies in its pipeline , including the first three AI-designed drug candidates to enter phase-one clinical trials – the first step in testing a new treatment in humans . Headquartered in Oxford Science Park and listed on New York ’ s Nasdaq exchange , Mileva is hopeful that “ Excscientia will become the next AstraZeneca . The academic credibility of the people involved gives me confidence that it can ”.
Wise has pioneered low-cost , supertransparent international money transfers .
/ 20 / trustnet . com